Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks

WSJDec 12 09:23 ET

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.

Barrons08:32 ET

NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD

Zacks 08:00 ET

Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.

The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.

Zhitong Finance03:43 ET

Here's Why Novo Nordisk A/S (NVO) Fell in Q3

Yahoo FinanceDec 12 09:46 ET

Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound

BenzingaDec 12 09:38 ET